
MannKind (MNKD) Stock Forecast & Price Target
MannKind (MNKD) Analyst Ratings
Bulls say
MannKind is a biopharmaceutical company that currently has three products in the market with potential for significant upside potential from its royalty and collaboration revenue streams. The company has a strong balance sheet, with a cash balance of $134M after settling its remaining senior convertible notes. MannKind's potential for success in the pediatric market with its insulin product, Afrezza, could be a major driver for revenue growth in the future. The company also has multiple other significant catalysts in 2026, including a potential label expansion for its product used to treat fluid buildup in heart failure patients, that could lead to a compelling risk-reward scenario for investors.
Bears say
MannKind is facing numerous challenges including commercial execution risks, clinical trial risks, and regulatory risks, which could hinder the success of its flagship products Afrezza, Furoscix, and V-Go. Additionally, the pending FDA decision on the ReadyFlow autoinjector for Furoscix could bring significant growth potential, but success is not guaranteed and delays or rejections could have a negative impact on the stock price. Furthermore, the company's valuation and price target are based on a discounted cash flow model with a 10.2% WACC and a 13.0x exit multiple on 2031 estimates, which reflects the inherent risk and uncertainty in the company's future performance.
This aggregate rating is based on analysts' research of MannKind and is not a guaranteed prediction by Public.com or investment advice.
MannKind (MNKD) Analyst Forecast & Price Prediction
Start investing in MannKind (MNKD)
Order type
Buy in
Order amount
Est. shares
0 shares